Management of partially platinum-sensitive relapsed ovarian cancer

European Journal of Cancer, Supplement

Volumn 6, Issue 4, 2008, Pages 16-21

  Kaye, Stanley B ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Anthracyclines; Antineoplastic agents; Carboplatin; Doxorubicin; Ovarian neoplasms; Taxoids

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN;

ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING;

EID: 40249100133     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2007.12.003     Document Type: Article

References (25)

1. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results [see comments]. J Natl Cancer Inst 92 9 (2000) 699-708
2. Pérez-López M.E., Curiel T., Gómez J.G., and Jorge M. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 18 (2006) 611-617
3. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer; the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
4. Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol/Hematol doi:10.1016/j.critrevonc.2007.04.004.
5. See H.T., Freedman R.S., Kudelka A.P., et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 15 (2005) 209-216
6. Kavanagh J., Tresukosol D., Edwards C., et al. Carboplatin reintroduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13 (1995) 1584-1588
7. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl. 5 (2002) 20-28
8. Herzog T.J. Recurrent ovarian cancer: how important is it to treat to disease progression?. Clin Cancer Res 10 (2004) 7439-7449
9. ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 (1997) 2183-2193
10. ten Bokkel Huinink W., Lane S.R., Ross G.A., and on behalf of the International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15 (2004) 100-103
11. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
12. Gordon A.N., Tonda M., Sun S., Rackoff W., and on behalf of the Doxil Study 30-49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95 (2004) 1-8
13. O'Byrne K.J., Bliss P., Graham J.D., et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer (abstract 808). Proc Am Soc Clin Oncol 21 (2002) 203a
14. Ferrandine G., Lorusso D., Pignata S., et al. A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxirubicin (PLD) in progressive/recurrent ovarian cancer (OC). 2007 ASCO meeting proceedings part I. J Clin Oncol 18S (2007) LBA5506
15. Gordon A.N., and Teitelbaum A. Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer (abstract and poster). Eur J Cancer Suppl 1 (2003) S51
16. Pignata S., Odicino F., Scambia G., et al. Extending the platinum-free interval (PFI) with a non-platinum therapy in platinum (P)-sensitive recurrent ovarian cancer (OC): results from the SOCRATES retrospective study. 2006 ASCO annual meeting proceedings part I. J Clin Oncol 15 18S (2006) 5093
17. Pfisterer J., Plante M., Vergote I., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup trial of the AGO-OVAR, and the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (2006) 4699-4707
18. Ferrero J.-M., Weber B., Geay J.-F., et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18 (2007) 263-268
19. Alberts D.S., Liu P.Y., Wilczynski S., et al. Phase III randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: Southwest Oncology Group Protocol S0200. 2007 ASCO meeting proceedings part I. J Clin Oncol 25 18S (2007) 5551
20. Sessa C., DeBrand F., Perotti A., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23 (2005) 1867-1874
21. Andreopoulou E., Gaiotti D., Kim E., et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 18 (2007) 716-721
22. Collins Y., and Lele S. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. J Natl Med Assoc 97 (2005) 1414-1416
23. Gifford G., Paul J., Vasey P.A., Kaye S.B., and Brown R. Group obotSGCT. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10 (2004) 4420-4426
24. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., and Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60 (2000) 6039-6044
25. Lee C., Appleton K., Plumb J., et al. A Phase I trial of decitabine in combination with carboplatin, both given 4 weekly by i.v. injection in patients with advanced solid tumours. Proc Am Soc Clin Oncol 23 (2004) 128